GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Spectrum Pharmaceuticals, Inc. (SPPI) [hlAlert]

Rating:
Buy SPPI
down 0.53 %

Spectrum Pharmaceuticals, Inc. (SPPI) rated Buy with price target $11.50 by Auriga

Posted on: Friday,  Sep 30, 2011  8:25 AM ET by Auriga

Auriga rated Buy Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on 09/30/2011, when the stock price was $7.53. Since
then, Spectrum Pharmaceuticals, Inc. has lost 0.53% as of 12/04/2015's recent price of $7.49.
If you would have followed this Auriga's recommendation on SPPI, you would have lost 0.53% of your investment in 1526 days.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company?s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Auriga operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/30/2011 8:25 AM Buy
None
7.53 11.50
as of 12/30/2011
1 Week down  -0.94 %
1 Month up  5.63 %
3 Months up  94.28 %
1 YTD up  94.28 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy